Xyzagen to Present New Kv7 Channel Opener Chemistry at American Epilepsy Society 2024 Annual Meeting

Xyzagen to Present New Kv7 Channel Opener Chemistry at American Epilepsy Society 2024 Annual Meeting

Pittsboro, NC — November 11, 2024 — Xyzagen’s neurology focused drug development and research team, is proud to announce it’ll be presenting a poster on new Kv7 channel opener chemistry.  This presentation will take place at the upcoming American Epilepsy Society (AES) Annual Meeting 2024, December 6-10 in Los Angeles, California.

The poster, titled “New Kv7 Channel Opener Chemistry for Treatment of Seizures,” will be presented at poster session 1.396 on Saturday, December 7, 2024, from 12-2pm.

 

About Xyzagen, Inc.:

Xyzagen augments a client’s pharmacology and pharmacokinetics drug development team.  As a leading pharmacokinetics consultancy and contract research organization with wet lab and rodent vivarium facilities, Xyzagen is able to push model informed drug development into its First-in-Rat® and First-in-Mouse® discovery platforms as well as support late stage clinical noncompartmental PK, PopPK and Quantitative Medicine. Our knowledge in pharmacology/pharmacogenomics and in vitro/in vivo pharmacokinetics allows the client to expand their core scientific team during the critical period of candidate selection up to the PreIND meeting and through clinical development and the preNDA meeting. We’re a boutique organization which allows for small clients and CROs to work directly with experts. 

 

Xyzagen has partnered with 100+ life science innovators, including early NIH-funded biotech’s, small and mid-size pharma companies, and venture capital firms.

For more information about Xyzagen and their services, please visit www.xyzagen.com or contact [email protected].

Media Contact:

Christopher Crean
Founder & CEO,
Xyzagen, Inc.
Phone: (919)-762-2072
Email: [email protected]

[LinkedIn]